Product category:
Clinical chemistry analysis
News Release from: Bespak Europe
Edited by the Laboratorytalk Editorial
Team on 07 November 2002
Partnership in nasal drug delivery RandD
Collaboration will form a research and product development partnership for the development and commercialisation of new intellectual property
Bespak has announced the signing of a partnership agreement with Lyfjathróun Biopharmaceuticals, the Icelandic drug delivery company The collaboration will form a research and product development partnership for the development and commercialisation of new intellectual property
This article was originally published on Laboratorytalk on 14 Oct 2003 at 8.00am (UK)
Related stories
It gets right up your nose
Next generation nasal device is capable of delivering an accurate single dose of a wide range of therapeutic agents
Bespak welcomes European approval of Exubera
Bespak, in conjunction with Nektar Therapeutics, has developed the manufacturing process for Exubera's inhalation device which it will manufacture at its purpose designed facility in Milton Keynes
Bespak and Lyfjathróun aim to identify, characterise and develop novel proprietary formulations of drug candidates for delivery via the nasal passages.
Additionally, the partnership seeks to establish a pipeline of products with a focus on those formulations that extend pharmaceutical patents, improve bioavailability and/or improve the efficacy of defined drugs and pharmaceuticals.
Bespak will provide marketing and drug delivery device technical support.
Lyfjathróun will provide the facilities, technologies and personnel necessary for all pre-clinical work as well as for the clinical development and validation of new IPR.
The companies have already set up a project team, which has commenced work.
Mark Throdahl, chief executive officer of Bespak, stated: "This partnership is extremely exciting for us as we progress to the next stage of our nasal drug delivery programme.
This relationship is consistent with our nasal business strategy to date - of providing innovative, complete solutions to our pharmaceutical partners in this rapidly emerging sector - and brings together Bespak's considerable knowledge and experience in device development with the formulation experience and capabilities of Lyfjathr¢un.
"Professor Gizurarson is a renowned world-class expert in the delivery of drugs through the nasal cavity and advises the US Food and Drug Administration in this specialist area - we look forward to working with him and his team." Sveinbjörn Gizurarson, CEO of Lyfjathróun Biopharmaceuticals, added: "We regard this agreement with Bespak as an important milestone.
Through this partnership agreement and through Bespak's international experience and know-how in development and marketing, we feel that together we are now well positioned to take a leading role in the development of intranasally delivered drugs.".
• Bespak Europe: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
